南新欲收购默克仿制药子公司

　　Ranbaxy， India's largest pharmaceutical company， is considering linking up with private equity firms to bid for the generic drugs unit of Germany's Merck as it embarks on an aggressive global expansion.

　　Acquiring Merck Generics would put Ranbaxy in a much stronger position in important global markets “and make us the seventh-largest generic maker globally”， Malvinder Mohan Singh， the company's chief executive， told the Financial Times.

　　The move comes as Merck reported strong fourth-quarter profits. It said this month it was considering whether to sell the generics unit to help fund its

　　Merck's shares have risen sharply on the back of strong interest from potential purchasers， with preliminary bids likely during February in a deal that analysts say could value its business at up to

　　印度最大制药企业南新制药公司在积极着手进行全球扩张之时，正考虑与私人股本公司结盟，共同竞标德国默克旗下的仿制药子公司Merck Generics。

　　南新公司首席执行官马尔文德·莫汉·辛格表示，收购Merck Generics将极大提升南新公司在全球市场的重要地位，让该公司成为“全球第七大仿制药生产企业”。

　　默克刚刚公布了强劲的2006年第四季度业绩。该公司本月表示正在考虑是否出售该仿制药子公司，以便为去年9月以105亿欧元收购瑞士生物技术公司Serono的交易提供资金。

　　在潜在收购方表示出浓厚兴趣后，默克股价大幅上扬。潜在收购方可能在2月份提出初步报价。分析师认为，初步报价对该项业务的估价可能高达40亿欧元（合52亿美元）。